Drug intelligence / Profile preview

MEDI8367

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

MEDI8367 is a monoclonal antibody developed by AstraZeneca for the treatment of chronic kidney disease. It acts as an inhibitor of transforming growth factor beta (TGFβ) by targeting integrin beta-8 (ITGB8), thereby blocking TGFβ activation. The drug was administered subcutaneously in clinical trials and reached Phase 1 development before being discontinued for strategic reasons.

Other names: MEDI-8367MEDI8367MEDI 8367

Targets

ITGB8 (Integrin beta-8)

Beyond the preview

Go deeper on MEDI8367.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI8367.

Explore the full profile